ALSO NOTED: Meda buys late-stage drugs;Debiopharm licenses peptide;and much more...

> How might drugmakers navigate the rocky waters of generic competition, cautious regulators, safety scandals, globalization, and so on? Seek help with the itinerary from an expert, perhaps. At least six top U.S. drugmakers have done this, putting strategy gurus in top offices. Report

> Meda has paid $20 million for the exclusive world-wide commercialization rights from Orexo of two patented drugs in late development phase; Sublinox and OX-NLA. Release

> Analytical NanoTechnologies has inked an agreement to acquire the entire issued share capital of Microarray for £1 million. Report

> Debiopharm Group has inked an option and license agreement with Airmid to develop an ShK peptide called Debio 0824, a potassium channel blocker currently in early preclinical development for autoimmune diseases. Release

> Introgen Therapeutics says that ADVEXIN Phase III clinical trial data in patients with recurrent head and neck cancer confirm earlier Phase II results of ADVEXIN efficacy. Release

> Alfacell announced that Dr. Intae Lee with the University of Pennsylvania has reported that Alfacell's Onconase (ranpirnase) could be a promising radiation sensitizer for lung cancer treatment. Release

> Nuvelo announced preclinical data demonstrating the mechanism of action and the potent therapeutic activity of NU206 (R-spondin1) in chemotherapy or radiation-induced oral mucositis models. Release

> Misleading minutes, swearing execs--just another day at the office for Vytorin's critics. Report

> If you had any doubt why Pfizer, GlaxoSmithKline, and other Big Pharma companies are drooling over business in the developing world, take a look at a new Deutsche Bank report on the Indian drug market. Report

And Finally… Co-pays on some expensive biotech drugs can now climb as high as 33 percent. Article

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.